DOI: http://dx.doi.org/10.18203/issn.2454-5929.ijohns20212450

Post-COVID rhinocerebral mucormycosis: an otolaryngologists nightmare

Samir V. Joshi, Nimita Dubey, Rajesh R. Havaldar, Amish Wakhlu

Abstract


Background: Rhinocerebral mucormycosis which was considered to be a rare occurrence in the pre-COVID era is currently emerging as a life-threatening disease with seemingly poor prognosis in post COVID recovered patients. Prompt diagnosis with urgent surgical and medical management is vital to a positive outcome.

Methods: A retrospective observational study and analysis was done among patients of biopsy proven mucormycosis with preceding history of COVID 19 disease between March 2021 to April 2021 in a tertiary care state run hospital at Pune coinciding with the sudden surge and second COVID 19 wave.

Results: 20 0ut of 23 patients were having a history of type 2 diabetes mellitus for a mean duration of 4±3.5 years. The most common presenting complaint was unilateral facial swelling, periorbital pain, swelling and oedema in 18 out of 23 patients. All patients had COVID infection within the last one month of presentation with mean duration of 18±8.4 days. Out of 23 patients 16 survived while 19 patients had permanent vision loss and ophthalmoplegia.

Conclusions: Establishing the possibility of invasive secondary fungal infections in patients with history of COVID-19 infection especially in patients with pre-existing risk factors should raise high index of suspicion. Prompt early diagnosis and treatment should be started to reduce morbidity and mortality.


Keywords


Post COVID, Rhinocerebral mucormycosis, Functional endoscopic sinus surgery, Amphotericin

Full Text:

PDF

References


Eucker J, Sezer O, Graf B, Possinger K. Mucormycoses. Mycoses. 2001;44:253-60.

Wagner L, de Hoog S, Alastruey-Izquierdo A, Voigt K, Kurzai O, Walther G. A Revised Species Concept for Opportunistic Mucor Species Reveals Species-Specific Antifungal Susceptibility Profiles. Antimicrob Agents Chemother. 2019;63(8):e00653-19.

Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2005;2(4).

Wagner L, de Hoog S, Alastruey-Izquierdo A, Voigt K, Kurzai O, Walther G. A Revised Species Concept for Opportunistic Mucor Species Reveals Species-Specific Antifungal Susceptibility Profiles. Antimicrob Agents Chemother. 2019;63(8):e00653-19.

AK AK, Gupta V. Rhino-orbital Cerebral Mucormycosis. [Updated 2021 Feb 8]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021. Available at: https://www.ncbi. nlm.nih.gov/books/NBK557429. Accessed on 8 April, 2021.

Management guidelines. Available at: https://www.icmr.gov.in/pdf/covid/techdoc/COVID 19_22042021_v1.pdf. Accessed on 8 April, 2021.

Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi (Basel). 2019;5(1):26.

Bhandari J, Thada PK, Nagalli S. Rhinocerebral Mucormycosis. [Updated 2020 Nov 23]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021. Available at: https://www.ncbi. nlm.nih.gov/books/NBK559288/. Accessed on 8 April, 2021.

Hosseini SM, Borghei P. Rhinocerebral mucormycosis: pathways of spread. Eur Arch Otorhinolaryngol. 2005;262(11):932-8.

Clinical management protocol for COVID-19. 2020. https://www.mohfw.gov.in/pdf/ClinicalManagementProtocolforCOVID19.pdf. Accessed on 4 April, 2021.

Dexamethasone in hospitalized patients with Covid-19 - preliminary report. The RECOVERY Collaborative Group. New Engl Med. 2020;4(1).

COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. 2021. https://www.covid19treatmentguidelines.nih.gov/. Accessed on 8 April, 2021.

Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19 Am J Emerg Med. 2020;4(2).

India State-Level Disease Burden Initiative Diabetes Collaborators. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Health. 2018;6(12):e1352-62.

COVID-19 India statistics, Maharashtra. Available at: https://www.covid19india.org/state/MH. Accessed on 8 April, 2021.

Spellberg B, Ibrahim AS. Recent advances in the treatment of mucormycosis. Current infectious disease reports. 2010;12(6):423-9.